SCM
NTLA icon

Sterling Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Sterling Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.1K Sell
2,724
-955
-26% -$13.4K ﹤0.01% 1603
2026
Q1 		$47.2K Sell
3,679
-2,380
-39% -$30.3K ﹤0.01% 1666
2025
Q4 		$54.5K Sell
6,059
-816
-12% -$11.2K ﹤0.01% 1771
2025
Q3 		$119K Buy
6,875
+4,155
+153% +$51.2K ﹤0.01% 1474
2025
Q2 		$25.5K Buy
2,720
+969
+55% +$7.96K ﹤0.01% 1702
2025
Q1 		$12.4K Sell
1,751
-1,447
-45% -$14.6K ﹤0.01% 1797
2024
Q4 		$37.3K Buy
3,198
+2,867
+866% +$44.7K ﹤0.01% 1693
2024
Q3 		$6.8K Buy
+331
New +$7.63K ﹤0.01% 1659

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Sterling Capital Management's NTLA Position: Q2 2026 in Review

Sterling Capital Management reduced its Intellia Therapeutics (NTLA) stake by 26% in Q2 2026, selling an estimated $13.4K and leaving 2,724 shares worth $46.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1603.

Sterling Capital Management first reported a position in NTLA in Q3 2024 and has held it in 8 quarters since. The position peaked at $119K in Q3 2025. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Sterling Capital Management held 2,724 shares of Intellia Therapeutics worth $46.1K as of Q2 2026.
  • Sterling Capital Management sold 955 Intellia Therapeutics shares in Q2 2026, an estimated $13.4K.
  • Intellia Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1603 holding.
  • Sterling Capital Management first reported a position in Intellia Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Intellia Therapeutics position peaked at $119K in Q3 2025.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.